Sun Pharma's focus on specialty drugs pays off https://ift.tt/jgFQTqn company's revenues grew 11% driven by strong growth posted by the India business and the global specialty sales in the US. A third of the company's revenues is earned each from India and the US. Sun's market share in India increased from 8.3% to 8.4% for the year ended September 2023.
NSE IFSC-SGX Connect may be fully operational by June https://ift.tt/XC89Iks this connectivity, global investors who are clients of SGX will be able to trade in Indian derivatives market remotely without having to set up a shop in India. Currently, only a few trades are being executed through the route.
Comments
Post a Comment